A5001799635- Influenza Virus Research Studies
- Respiratory viral infections research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Immune Response and Inflammation
- Viral gastroenteritis research and epidemiology
- T-cell and B-cell Immunology
- Pneumonia and Respiratory Infections
- Immunotherapy and Immune Responses
- Animal Disease Management and Epidemiology
- Viral Infections and Immunology Research
- Escherichia coli research studies
- Viral Infections and Vectors
- Receptor Mechanisms and Signaling
- Heat shock proteins research
- Chemical Synthesis and Analysis
- Neuroscience of respiration and sleep
- SARS-CoV-2 and COVID-19 Research
- Glycosylation and Glycoproteins Research
- Neonatal Respiratory Health Research
- Ubiquitin and proteasome pathways
- interferon and immune responses
- Transgenic Plants and Applications
- Mass Spectrometry Techniques and Applications
- Viral Infections and Outbreaks Research
Center for Biologics Evaluation and Research
2013-2025
United States Food and Drug Administration
2009-2025
Food and Drug Administration
2016
Global Viral
2012-2013
Weatherford College
2011
The Ohio State University
2007
Johns Hopkins University
1999-2002
Vanderbilt University
2000
St. Jude Children's Research Hospital
1991-1996
University of Alabama at Birmingham
1995
Transgenic mice homozygous for a beta 2-microglobulin (beta 2-m) gene disruption and normal that had been treated with CD8-specific mAb were infected intranasally an H3N2 influenza A virus. Both groups of CD8T cell-deficient eliminated the virus from respiratory tract. Potent CTL activity was detected in lung lavage populations taken intact CD8+ T cell function, minimal levels cytotoxicity being found inflammatory cells obtained antibody-treated 2-m mutant mice. We therefore conclude can be...
Seasonal epidemics caused by influenza virus are driven antigenic changes (drift) in viral surface glycoproteins that allow evasion from preexisting humoral immunity. Antigenic drift is a feature of not only the hemagglutinin (HA), but also neuraminidase (NA). We have evaluated evolution each protein H1N1 and H3N2 viruses used vaccine formulations during last 15 y analysis HA NA inhibition titers cartography. As previously shown for HA, genetic did always lead to an change. The noncontinuous...
We have used a neuraminidase-deficient influenza virus, NWS-Mvi, which was selected by supplying bacterial neuraminidase in the medium (C. Liu and G. M. Air, Virology 194:403-407, 1993), to define role of virus replication. Electron microscopy showed that virions NWS-Mvi mutant assembled normally formed large aggregates associated with cell surfaces. The grown absence able carry out second round replication MDCK cells without added neuraminidase, indicating particles contained these were...
A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404 vaccine infectious at 104 and 105 plaque-forming units RSV-naive children broadly immunogenic >6 months old. Serum nasal antibody responses 1-2 month olds were restricted to IgA, had a dominant response G protein, no increase neutralizing activity. Nevertheless, there...
Antibodies to neuraminidase (NA), the second most abundant surface protein on influenza virus, contribute toward protection against influenza. The traditional thiobarbituric acid (TBA) method quantify NA inhibiting antibodies is cumbersome and not suitable for routine serology. An enzyme-linked lectin assay (ELLA) described by Lambre et al. (1990) a practical alternative measuring inhibition (NI) titers. This report describes optimization of ELLA NI titers in human sera A viruses, using H6N1...
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well first described case clinically significant to peramivir.
Antibody responses to influenza virus hemagglutinin provide protection against infection and are well studied. Less is known about the human antibody second surface glycoprotein, neuraminidase. Here, we assessed reactivity a panel of N1, N2, B neuraminidases in different age groups, including children, adults, elderly. Using enzyme-linked immunosorbent assays (ELISA), determined breadth, magnitude, isotype distribution neuraminidase historic, current, avian strains, as recent isolates which...
ABSTRACT Influenza A viruses, including H1N1 and H5N1 subtypes, pose a serious threat to public health. Neuraminidase (NA)-related immunity contributes protection against influenza virus infection. Antibodies the N1 subtype provide homologous heterologous as well challenge. Since neither strain-specific nor conserved epitopes of have been identified, we generated panel mouse monoclonal antibodies (MAbs) that exhibit different reactivity spectra with viruses used these MAbs map antigenic...
Abstract A(H1N1)pdm09 influenza A viruses predominated in the 2013–2014 USA season, and although most of these remain sensitive to Food Drug Administration-approved neuraminidase (NA) inhibitors, alternative therapies are needed. Here we show that monoclonal antibody CD6, selected for binding NA prototypic virus, A/California/07/2009, protects mice against lethal virus challenge. The crystal structure complex with CD6 Fab reveals a unique epitope, where heavy-chain complementarity...
For 50 years it has been known that antibodies to neuraminidase (NA) protect against infection during seasonal and pandemic influenza outbreaks. However, NA is largely ignored in the formulation standardization of our current vaccines. There are a number factors contributed this antigen being forgotten, including lack an easily performed test measure antibody. With availability test, possible show its independent contribution protection various situations. The challenge now make include...
The spectrum of TCR usage has been analyzed for virus-specific CD8+ T cells isolated from the regional mediastinal lymph modes and lung by bronchoalveolar lavage (BAL) C57BL/6 (B6) mice with influenza pneumonia. Lymphocytes were recovered during acute phase primary response in infected an H3N2 (A/HKx31) virus, or immune animals that secondarily challenged H1N1 virus (A/PR8). Cells taken directly BAL exhibited increase frequency V beta 8.3+/CD8+ cells. In addition, 20 to 50% proliferating...
Influenza A virus continues to cause annual epidemics. The emergence of avian viruses in the human population poses a pandemic threat, and has highlighted need for more effective influenza vaccines antivirals. Development such therapeutics would be enhanced by use small-animal model that is permissive replication virus, which reagents are available dissect host response. presented nasal pulmonary infection adult inbred cotton rats ( Sigmodon hispidus ) does not require viral ‘adaptation’. It...
are warranted to evaluate whether ibrutinib impairs or improves vaccine response relative other treatments.Limitations of the study include a small sample size and incomplete laboratory confirmation influenza infection.Furthermore, defining an appropriate control group may prove challenging; treatment-naive patients often have immune impairment related their disease while in remission after chemoimmunotherapy experience immunosuppressive effects treatment. 7Conclusions | Our data show that...
The effectiveness of seasonal influenza vaccines against circulating A(H1N1)pdm09 viruses has been modest in recent years, despite the absence antigenic drift HA, primary vaccine component. Human monoclonal antibodies identified sites NA that changed early after new pandemic virus emerged. reactivity ferret antisera demonstrated from 2013 onward. Passive transfer serum raised A/California/7/2009 was less effective than homologous protecting mice a with more virus, A/Michigan/45/2015. Given...
Antibody titers decrease with time following influenza vaccination, raising concerns that vaccine efficacy might wane. However, the relationship between since vaccination and protection is unclear.Time-varying (VE[t]) was examined in healthy adult participants (age range, 18-49 years) a placebo-controlled trial of inactivated (IIV) live-attenuated (LAIV) performed during 2007-2008 season. Symptomatic respiratory illnesses were laboratory-confirmed as influenza. VE(t) estimated by fitting...
Immune responses at mucosal sites are thought to be initiated in the draining lymph nodes, where dendritic cells present viral antigens and induce naive T proliferate become effectors. Formal proof that antigen-presenting (APC) do indeed localize regional nodes has been lacking for infections of respiratory tract. Influenza virus was detected mediastinal (MLN) early after intranasal inoculation, with peak titers this tissue measured 2 days postinfection. Virus-specific cytotoxic T-lymphocyte...